Review



human p75ecd standard  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems human p75ecd standard
    Fig. 2: Longitudinal biomarker trajectories. Longitudinal trajectories of (a) serum NfL; (b) serum pNfH; and (c) urinary <t>p75ECD.</t> Y-axis shows percent change in each biomarker compared to baseline, plotted on a log scale. The faint grey dotted line illustrates the linear estimate of biomarker change over time. Error bars represent 95% confidence intervals (CI), widened at later time points due to participant attrition over time and fewer biomarker data available. NfL and pNfH were measured in duplicate; p75ECD quantified with a median of 3 replicates. Single NfL and pNfH values from the 18-month visit of a single participant have been excluded (see footnote to Table 3 for detailed explanation).
    Human P75ecd Standard, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human p75ecd standard/product/R&D Systems
    Average 94 stars, based on 7 article reviews
    human p75ecd standard - by Bioz Stars, 2026-05
    94/100 stars

    Images

    1) Product Images from "Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis."

    Article Title: Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis.

    Journal: EBioMedicine

    doi: 10.1016/j.ebiom.2024.105323

    Fig. 2: Longitudinal biomarker trajectories. Longitudinal trajectories of (a) serum NfL; (b) serum pNfH; and (c) urinary p75ECD. Y-axis shows percent change in each biomarker compared to baseline, plotted on a log scale. The faint grey dotted line illustrates the linear estimate of biomarker change over time. Error bars represent 95% confidence intervals (CI), widened at later time points due to participant attrition over time and fewer biomarker data available. NfL and pNfH were measured in duplicate; p75ECD quantified with a median of 3 replicates. Single NfL and pNfH values from the 18-month visit of a single participant have been excluded (see footnote to Table 3 for detailed explanation).
    Figure Legend Snippet: Fig. 2: Longitudinal biomarker trajectories. Longitudinal trajectories of (a) serum NfL; (b) serum pNfH; and (c) urinary p75ECD. Y-axis shows percent change in each biomarker compared to baseline, plotted on a log scale. The faint grey dotted line illustrates the linear estimate of biomarker change over time. Error bars represent 95% confidence intervals (CI), widened at later time points due to participant attrition over time and fewer biomarker data available. NfL and pNfH were measured in duplicate; p75ECD quantified with a median of 3 replicates. Single NfL and pNfH values from the 18-month visit of a single participant have been excluded (see footnote to Table 3 for detailed explanation).

    Techniques Used: Biomarker Discovery



    Similar Products

    human p75ecd standard  (R&D Systems)
    94
    R&D Systems human p75ecd standard
    Fig. 2: Longitudinal biomarker trajectories. Longitudinal trajectories of (a) serum NfL; (b) serum pNfH; and (c) urinary <t>p75ECD.</t> Y-axis shows percent change in each biomarker compared to baseline, plotted on a log scale. The faint grey dotted line illustrates the linear estimate of biomarker change over time. Error bars represent 95% confidence intervals (CI), widened at later time points due to participant attrition over time and fewer biomarker data available. NfL and pNfH were measured in duplicate; p75ECD quantified with a median of 3 replicates. Single NfL and pNfH values from the 18-month visit of a single participant have been excluded (see footnote to Table 3 for detailed explanation).
    Human P75ecd Standard, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human p75ecd standard/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    human p75ecd standard - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    recombinant human p75ecd standard  (R&D Systems)
    90
    R&D Systems recombinant human p75ecd standard
    Fig. 2: Longitudinal biomarker trajectories. Longitudinal trajectories of (a) serum NfL; (b) serum pNfH; and (c) urinary <t>p75ECD.</t> Y-axis shows percent change in each biomarker compared to baseline, plotted on a log scale. The faint grey dotted line illustrates the linear estimate of biomarker change over time. Error bars represent 95% confidence intervals (CI), widened at later time points due to participant attrition over time and fewer biomarker data available. NfL and pNfH were measured in duplicate; p75ECD quantified with a median of 3 replicates. Single NfL and pNfH values from the 18-month visit of a single participant have been excluded (see footnote to Table 3 for detailed explanation).
    Recombinant Human P75ecd Standard, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human p75ecd standard/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    recombinant human p75ecd standard - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 2: Longitudinal biomarker trajectories. Longitudinal trajectories of (a) serum NfL; (b) serum pNfH; and (c) urinary p75ECD. Y-axis shows percent change in each biomarker compared to baseline, plotted on a log scale. The faint grey dotted line illustrates the linear estimate of biomarker change over time. Error bars represent 95% confidence intervals (CI), widened at later time points due to participant attrition over time and fewer biomarker data available. NfL and pNfH were measured in duplicate; p75ECD quantified with a median of 3 replicates. Single NfL and pNfH values from the 18-month visit of a single participant have been excluded (see footnote to Table 3 for detailed explanation).

    Journal: EBioMedicine

    Article Title: Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis.

    doi: 10.1016/j.ebiom.2024.105323

    Figure Lengend Snippet: Fig. 2: Longitudinal biomarker trajectories. Longitudinal trajectories of (a) serum NfL; (b) serum pNfH; and (c) urinary p75ECD. Y-axis shows percent change in each biomarker compared to baseline, plotted on a log scale. The faint grey dotted line illustrates the linear estimate of biomarker change over time. Error bars represent 95% confidence intervals (CI), widened at later time points due to participant attrition over time and fewer biomarker data available. NfL and pNfH were measured in duplicate; p75ECD quantified with a median of 3 replicates. Single NfL and pNfH values from the 18-month visit of a single participant have been excluded (see footnote to Table 3 for detailed explanation).

    Article Snippet: Human p75ECD standard was from R&D Systems (Lys29-Asn250; #367-NR).

    Techniques: Biomarker Discovery